Get the Stockscreener App
6.11
0.66%
0.04
After Hours:
6.11
Cvrx Inc stock is traded at $6.11, with a volume of 245.91K.
It is up +0.66% in the last 24 hours and down -23.43% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$6.07
Open:
$6.13
24h Volume:
245.91K
Relative Volume:
0.72
Market Cap:
$162.13M
Revenue:
$56.65M
Net Income/Loss:
$-53.31M
P/E Ratio:
-2.9889
EPS:
-2.0442
Net Cash Flow:
$-40.75M
1W Performance:
+2.00%
1M Performance:
-23.43%
6M Performance:
-37.97%
1Y Performance:
-8.12%
1-Day Range:
$6.09
$6.43
1-Week Range:
$5.70
$6.43
52-Week Range:
$4.3701
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
6.11 | 161.07M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
Understanding Momentum Shifts in (CVRX) - Stock Traders Daily
CVRx, Inc.Common Stock (NQ: CVRX - The Chronicle-Journal
Clinical research teams accelerate progress in treatment options, CVRx asserts - Traders Union
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders - simplywall.st
CVRx to present at William Blair Growth Stock Conference on June 2, 2026 - Pluang
CVRx to Present at the William Blair 46th Annual Growth Stock Conference - The Manila Times
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill - Traders Union
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy - Yahoo Finance
CVRx rebounds as Humana issues Medicare policy for Barostim - MSN
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight - AD HOC NEWS
Number of shareholders of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRx Gains Momentum With Revenue Growth, BENEFIT-HF Progress and Humana Coverage Win - TipRanks
CVRx (CVRX) reports Q1 loss, beats revenue estimates - MSN
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report - Yahoo Finance
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy - Sahm
Humana (HUM) Expands Medicare Advantage Coverage for Barostim Th - GuruFocus
CVRx earns Humana Medicare Advantage win for Barostim - MassDevice
CVRx stock gains as Humana to cover Barostim - Seeking Alpha
Humana issues Medicare Advantage coverage for CVRx Barostim therapy By Investing.com - Investing.com Nigeria
Humana issues Medicare Advantage coverage for CVRx Barostim therapy - Investing.com
Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal - Traders Union
CVRx announces Humana Medicare Advantage coverage policy for Barostim therapy - marketscreener.com
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
CVRx Inc | 10-Q: Q1 2026 Earnings Report - Moomoo
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - Yahoo Finance
TradingKey - TradingKey
CVRx Earnings Call Highlights Growth Amid Ongoing Losses - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CVRx stock (US12674F1003): Q1 revenue jumps 20% to $14.8M - AD HOC NEWS
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - Moomoo
J.P. Morgan Maintains CVRx Inc(CVRX.US) With Sell Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for CVRx Inc(CVRX.US), With a Forecast Between $6 to $12 - Moomoo
CVRx, Inc. (NASDAQ:CVRX) Q1 2026 Earnings Call Transcript - Insider Monkey
CVRx revenue up 20% to USD 14.8M in Q1 2026 - Medical Buyer
CVRx, Inc. 1Q 2026: Revenue $14.77M, EPS ($0.5) — 10-Q Summary - TradingView
CVRx (NASDAQ: CVRX) grows Q1 revenue 20% as net loss narrows - Stock Titan
Avoiding Lag: Real-Time Signals in (CVRX) Movement - Stock Traders Daily
CVRx earnings beat by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises By Investing.com - Investing.com Australia
CVRx Q1 Earnings Call Highlights - sharewise.com
Earnings call transcript: CVRx beats Q1 2026 forecasts, stock rises - Investing.com India
CVRx revenue rises 20 percent in first quarter as U.S. operations expand - Traders Union
CVRX: Q1 2026 delivered strong revenue growth, margin expansion, and strategic progress in U.S. heart failure therapy - TradingView
CVRx (CVRX) Q1 2026 Earnings Call Transcript - AOL.com
CVRX: Q1 2026 revenue grew 20% with strong U.S. performance and improved gross margin - TradingView
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):